CION Ameerpet
Ovarian cancer responds to chemotherapy better than most solid cancers do — which is why chemotherapy is not an extra here, it is half the treatment. The usual first-line course is six cycles, three weeks apart, of a platinum-based drug with a taxane-class partner. This page walks through what that means in practice, from the blood test before cycle one to the scan after cycle six.
If you have been searching chemotherapy ovarian cancer since the diagnosis, you are probably trying to answer three questions at once: what will they give me, how long will it take, and will it work. This page answers those three, in that order, and leaves out the parts you do not need yet.
The first thing worth knowing is genuinely encouraging. Ovarian cancer responds to chemotherapy more reliably than most solid cancers do. That is why chemotherapy here is not an add-on to surgery — it is half of the treatment. Surgery removes what can be seen; chemotherapy deals with the microscopic disease left across the abdominal lining that no operation can lift out. Most women, including many with stage III disease, reach remission once the two are combined.
It is also why the plan looks similar for a lot of women. Platinum chemotherapy has been the backbone of ovarian cancer treatment for close to thirty years, paired with a taxane-class drug, because nothing has displaced that combination as a starting point. What is tailored to you is the sequence, the schedule, the dose and what follows the course — rarely the backbone itself. The complete ovarian cancer guide sets out where chemotherapy sits in the wider pathway.
Ovarian cancer shrinks with chemotherapy more reliably than most solid tumours, which is why an advanced stage at diagnosis is not the end of the conversation.
First-line treatment is normally six cycles three weeks apart — about four and a half months. When chemotherapy is given before surgery, the cycles are split around the operation.
A platinum-based drug with a taxane-class partner is the standard opening combination. Your oncologist should be able to explain any departure from it in one sentence.
More chemotherapy, given more often, is not automatically better. A Japanese trial, JGOG 3016, found that splitting the taxane-class drug into smaller weekly doses — a “dose-dense” schedule — delayed the cancer’s return compared with the standard three-weekly schedule. When the same approach was tested in Europe in the much larger ICON8 trial, it did not improve progression-free survival, and it caused more dose delays and reductions. Both results are real. The likely explanations lie in inherited differences in how these drugs are handled and in differences in surgery between the two populations. It is a good illustration of why a schedule is chosen for you, rather than the most intensive one being reached for by default. Source: Katsumata N et al., Lancet (2009); Clamp AR et al., Lancet (2019); NCCN Clinical Practice Guidelines, Ovarian Cancer.
This is what an ovarian cancer chemo regimen usually looks like when nothing unusual is going on. Your own plan may differ on any line here — and when it does, the reason should be explainable to you in plain language.
| The question | The usual answer | What changes it |
|---|---|---|
| Which drugs? | A platinum-based drug combined with a taxane-class drug, given together on the same day. | Kidney function, a previous severe reaction, existing nerve damage, or a rarer tumour type such as a germ cell or stromal tumour. |
| How many cycles? | Six, in most first-line plans. | Sometimes fewer for early-stage disease. When chemotherapy comes first, the six are usually split around the operation. |
| How often? | Once every three weeks. That three-week block is one cycle. | A weekly schedule is sometimes chosen for frailty or poor tolerance rather than for extra strength — see the trial evidence above. |
| How is it given? | Into a vein in the day-care unit, over roughly three to five hours including pre-medication. | A port or PICC line where veins are difficult. Delivery into the abdomen suits only a narrow group after optimal surgery. |
| Before or after surgery? | After debulking surgery, in most women. | Chemotherapy first where the disease is too extensive to remove safely at the outset, or where fitness for major surgery is borderline. |
| How is the effect judged? | Symptoms, clinical examination, the CA-125 trend and a CT scan at the end of the course. | A scan partway through if there is any doubt the treatment is working, so the plan can be changed early. |
| What comes next? | Maintenance therapy is considered for most women with advanced disease. | BRCA and HRD results, the stage, and how completely the disease responded to the chemotherapy. |
*A cycle means the whole three-week block, not the day of the infusion. When your oncologist says “cycle four”, that is the fourth block — you are further along than the number sounds.
Most of the dread before the first infusion is dread of the unknown. Here is the whole shape of a three-week cycle — from the blood test that clears it, through the week you will feel worst, to the week you will feel most like yourself.
The histopathology report has to be final, because subtype and grade change what is given. A staging CT of the chest, abdomen and pelvis gives the baseline that every later scan is compared against. Baseline bloods cover the full blood count, kidney function and liver function, and your height and weight are measured properly, because the dose is calculated from them rather than estimated.
Two other things should happen before the first infusion. Any existing numbness, tingling or hearing difficulty is documented, so later changes can be measured against a real baseline rather than a memory. And a decision is made about veins: if yours are difficult, a port or a PICC line placed before cycle one saves a great deal of distress over the following months. This is also when genetic testing should be set in motion — not at the end of the course.
You arrive at the day-care unit, the blood results from the previous day or two are reviewed, and treatment is confirmed or postponed on the spot. Pre-medication goes in first — anti-sickness medication, a steroid and an antihistamine — and it is the reason the day is longer than the chemotherapy alone would need. The two drugs then run one after the other. Most women are in the chair for three to five hours.
The nurses watch closely during the first minutes of each drug, because infusion reactions, when they happen, happen early and are managed on the spot. You can eat, read, sleep or have someone sit with you. Bring a shawl, water and a phone charger. Almost everyone goes home the same day.
Anti-sickness tablets are taken on a schedule for the first few days, not only when nausea appears — taken on time they work far better than taken in retrospect. The steroid given with the infusion often produces a lift on day one or two and a corresponding dip when it wears off, which many women mistake for the cancer, or for the chemotherapy failing. It is neither.
Aching muscles and joints, constipation, a metallic taste and poor appetite are common in this window. Fluids, small frequent meals and gentle movement help more than lying still does. If nothing will stay down, that is a call to the unit rather than something to endure.
White cells fall to their lowest around the middle of the cycle, usually somewhere between day seven and day fourteen. This is the window in which an ordinary infection can become serious quickly, and it is the single most important thing to understand about chemotherapy safety. Sensible precautions — hand hygiene, avoiding crowds and anyone obviously unwell, careful mouth care, freshly cooked food — matter most in this week.
A fever in this window is an emergency, not a wait-and-see. Hair thinning, if it is going to happen, also usually begins around the second or third week of the first cycle. For managing the day-to-day effects, see managing chemotherapy side effects in ovarian cancer.
Counts recover, appetite returns and most women feel close to normal in the last week of the cycle. Plan the things that matter to you here — a family event, a few days of work, a trip home to see people. Living around the cycle, rather than putting life on hold for four months, is genuinely better for how you come through treatment.
This is also the week to eat properly and to walk. Holding on to weight and muscle through chemotherapy is not a cosmetic concern: it affects how well you tolerate the next cycle and how quickly you recover once the course ends.
A day or two before each cycle, blood is taken to confirm that counts have recovered and that kidney and liver function still allow full doses. If white cells or platelets are still low, the cycle is delayed by a week, or the dose is reduced, or growth-factor support is added for the cycles that follow.
A delayed cycle feels like a setback and almost never is one. The course is designed with room for this. The aim is to complete the planned number of cycles at a dose you can actually tolerate — not to stay on the original calendar at any cost.
Dose reductions are common and they are not a sign that treatment has stopped working. Nerve symptoms in the fingers and toes are the commonest reason to modify the taxane-class drug, and reporting them early is what protects long-term hand function — numbness that is acted on tends to settle, numbness endured in silence for three more cycles often does not.
Occasionally a drug is changed altogether: for a severe allergic-type reaction, for kidney function that has fallen, or for hearing loss. There are alternatives within the same classes, and switching is a routine clinical decision rather than a crisis.
Most side effects can wait for the next clinic visit. These cannot. Infection while the white cell count is low is the one true emergency of chemotherapy, and it is very treatable when it is caught within hours rather than days.
Or shaking chills, even without a measured temperature. Call first — do not take paracetamol and wait to see, because it masks the fever.
New shortness of breath, a racing heart or chest pain needs same-day assessment rather than a wait-and-see at home.
If nothing stays down for several hours, dehydration follows quickly. Anti-sickness treatment can be changed — it is not something to endure.
A nosebleed that will not stop, bleeding gums, blood in urine or stool, or bruises appearing without any knock.
Or redness and pain around the port site. Clots and line infections are both commoner during chemotherapy and both need prompt review.
Rapidly increasing tingling or clumsiness in the hands or feet should be reported before the next cycle, not mentioned after it.
Put the day-care unit’s number in your phone before cycle one, and keep your chemotherapy record card with you — if you present anywhere else, it tells the treating team immediately what you have had and when.
Bring your histopathology report, your staging scan and the plan you have been given. A 45-minute consultation is long enough to say whether the sequence, the schedule and the number of cycles make sense for your situation — and to explain why, either way.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
The first consultation is free and runs about 45 minutes. Bring your reports — you will leave knowing what is being proposed, why, and what it will involve week by week.
None of this is decided by one person in five minutes. This is the sequence a medical oncologist works through, and every step of it should be explained to you before you sign a consent form.
Subtype and grade come first, because they decide how the cancer behaves. High-grade serous carcinoma is the commonest epithelial type and the most reliably platinum-sensitive. Germ cell and sex cord-stromal tumours are treated on entirely different plans, respond very well, and are often curable even when advanced — which is why the pathology report, and not the stage alone, drives the plan.
This turns on how extensive the disease is on the staging scan, and on whether removing all visible disease is realistic. Where it is not, chemotherapy is given first to shrink the disease before an interval operation. Both routes are standard practice. All ovarian cancer surgery is coordinated with specialist gynaecologic-oncology surgeons at partner centres, so this decision is made jointly rather than by the medical oncologist alone.
Your case is discussed by medical oncology, radiology, pathology and the coordinating surgical team together. A tumour board is where disagreements about sequence get settled with the scans on the screen — and it is the single best protection against a plan built on one person’s preference.
Full blood count, kidney and liver function, and accurate height and weight, because doses are calculated rather than standard. Existing nerve symptoms, hearing, and conditions such as diabetes or heart disease are documented, since they change what is used and what is watched for. These are the tests that change decisions — nothing is ordered for the sake of a fuller file.
BRCA testing, on blood and on the tumour, and HRD status where it applies, take weeks to come back, and they shape what happens after chemotherapy. Starting them during the course rather than after it is what makes an unhurried decision about maintenance therapy possible. Genetic counselling and testing are delivered in-house at CION.
You should leave with dates, not intentions: a mapped calendar of infusion days and blood-test days, the unit you will attend, and what to bring. Cycles are given in CION day-care units across 35+ centres in Telangana and Andhra Pradesh, so most women can be treated near home. Costs, insurance and scheme cover such as Aarogyasri are discussed before treatment starts rather than after it.
Response is judged on four things together: how you feel, what the examination shows, the direction of the CA-125 trend across cycles, and the CT scan at the end of the course. No single one of them decides anything. A CA-125 falling steadily is reassuring; one reading that ticks up is not a verdict, and is often a laboratory or inflammatory blip.
If the scan shows no measurable disease, that is called a complete response. It is worth being precise about what that means: imaging cannot see microscopic disease, so a complete response means the cancer is undetectable, not proven absent. That distinction is the whole reason maintenance therapy exists, and the reason follow-up continues for years afterwards.
You will also hear the phrase platinum-sensitive. It simply describes how long the cancer stays away after platinum-based treatment finishes — and if the disease ever returns, that interval guides what is offered next far more than the original stage does. It is a term for later. It does not need to shape how you feel at cycle three. What usually happens straight after the course is a discussion about maintenance therapy, which is treatment given to delay a recurrence, chosen largely on BRCA and HRD results.
Most women want a survival number at this point, and the honest answer is that the stage-specific figures you will find online mislead more than they inform. They are historical, so they predate current maintenance therapy; they average across substages and tumour subtypes that behave very differently; and they mix women who had all visible disease removed with women who did not. What CION can show you is its own outcome alongside the national one.
CION ovarian cancer patients alive at one year from diagnosis. *One-year survival, CION treated population.
The comparable national figure for ovarian cancer. *One-year survival; national registry data.
One-year survival is not a cure rate and not a prediction for any individual. Stage, subtype, how completely disease was removed and your general health matter far more to your own outlook.
*One-year survival rates. CION figures reflect CION’s treated patient population; national figures are drawn from published Indian cancer registry data. Survival statistics describe groups, not individuals — discuss your own prognosis with your treating oncologist.
Chemotherapy is the part of ovarian cancer treatment you will live with longest, and it is delivered by CION itself. Intravenous chemotherapy day care and maintenance therapy are in-house across 35+ centres in Telangana and Andhra Pradesh, which over a four-to-five-month course is not a small thing — it is the difference between a short trip every three weeks and a day of travelling into the city each time. BRCA and HRD testing, genetic counselling, nutrition support and survivorship follow-up are in-house too.
What CION does not do in-house is the surgery. Debulking, staging and interval cytoreductive surgery, along with HIPEC, intraperitoneal delivery and PET-CT, are coordinated with specialist gynaecologic-oncology surgeons at partner centres, and treatment given there may also be billed there. We would rather you knew that before you commit than discovered it in the middle of a course.
The first consultation is free and runs about 45 minutes — long enough to read the histopathology and the staging scan properly, which is what a plan should be built on. Every case that raises a question goes to a tumour board rather than to one doctor’s judgement. If the plan you have already been given is a sound one, you will be told so plainly instead of being offered a reason to switch. If it is not, you will be shown exactly what would change and why, in the wider context of ovarian cancer treatment in Hyderabad.
Free, unhurried, and long enough to go through the pathology report and staging scan that actually determine the chemotherapy plan.
Medical oncology, radiology, pathology and the coordinating surgical team review the sequence together, rather than one clinician deciding it alone.
Chemotherapy is delivered in-house across 35+ centres, so infusion days and blood tests can happen near where you live for the whole course.
Chemotherapy, maintenance therapy, genetic testing and counselling are ours. Surgery, HIPEC and PET-CT sit with partner centres — and we say so upfront.
*Chemotherapy, maintenance therapy, genetic counselling, BRCA and HRD testing, nutrition support and follow-up are delivered by CION. Ovarian cancer surgery, HIPEC, intraperitoneal chemotherapy and PET-CT are delivered at specialist partner centres and may be billed there.
First-line treatment for epithelial ovarian cancer is built on a platinum-based drug combined with a taxane-class drug, given together into a vein. That pairing has been the standard opening combination for close to thirty years because nothing has consistently beaten it. In selected cases an anti-angiogenic drug, which works by cutting off the tumour's blood supply, is added to the chemotherapy and continued afterwards. Germ cell and sex cord-stromal tumours, which are much less common and usually affect younger women, are treated with different combinations entirely and respond very well. Your oncologist should be able to explain in one sentence why your particular combination was chosen, and the specific drugs are a conversation for the consultation rather than for a web page.
Six cycles is the usual first-line course, given once every three weeks, which works out at about four and a half months from the first infusion to the last. Some early-stage cancers are treated with fewer. When chemotherapy is given before surgery rather than after it, the cycles are usually split around the operation, with three or four beforehand and the rest afterwards. A cycle means the entire three-week block and not just the day of the infusion, so being told you are on cycle four means you are further through the course than the number sounds. Cycles are sometimes delayed by a week if blood counts have not recovered, and that is planned for rather than a setback.
Both are standard, and the choice depends on how extensive the disease is and how fit you are for a major operation. Most commonly, debulking surgery comes first and chemotherapy follows to deal with what could not be removed. Where the scan shows disease too widespread to remove completely and safely at the outset, chemotherapy is given first to shrink it, and surgery follows partway through the course. Giving chemotherapy first is not a lesser option and does not mean the situation is hopeless. All ovarian cancer surgery at CION is coordinated with specialist gynaecologic-oncology surgeons at partner centres, so this decision is made jointly by the surgical and medical teams at a tumour board.
It is given into a vein in a day-care unit, and you go home the same day. Expect to be there roughly three to five hours. Much of that time is pre-medication, which is anti-sickness medication, a steroid and an antihistamine given before the chemotherapy to prevent reactions and nausea. The two drugs then run one after the other while the nursing team keeps a close eye on you, particularly during the first minutes of each. If your veins are difficult, a port or a PICC line placed before the first cycle makes every subsequent visit easier. You can eat, read or have someone sit with you throughout.
Four things are watched together: your symptoms, the clinical examination, the CA-125 trend across cycles, and a CT scan, usually at the end of the course. None of them decides anything alone. A CA-125 falling steadily cycle by cycle is a good sign, and a single reading that ticks up is not a verdict, because the marker also moves with inflammation and laboratory variation. Bloating settling, appetite returning and clothes fitting again are meaningful too. If there is real doubt about whether the treatment is working, a scan is arranged partway through so that the plan can be changed early rather than at the end.
Side effects are real and they are actively managed, which is a different thing from being unavoidable. Hair loss is likely with the standard combination and it usually begins around the second or third week of the first cycle; it grows back after treatment finishes, often with a change in texture. Nausea is far better controlled than its reputation suggests, provided anti-sickness tablets are taken on schedule rather than only when you feel sick. Fatigue, taste change, constipation and tingling in the fingers and toes are the other common ones. Tell your team early about numbness in particular, because acting on it protects long-term hand function. Our guide to managing chemotherapy side effects in ovarian cancer covers each of these in detail.
It describes how long ovarian cancer stays away after platinum-based chemotherapy finishes. Cancer that returns only after a long interval is called platinum-sensitive and usually responds well to platinum-based treatment again. Cancer that returns quickly is described as platinum-resistant and is treated with different drug classes instead. The term matters because that interval, rather than the original stage, guides what is offered if the disease ever comes back. It is a term for later, not for cycle three, and it is not a judgement on how you responded to the first course. Most high-grade serous ovarian cancer is platinum-sensitive at the outset, which is one of the reasons this cancer remains treatable even when it is advanced.
The first consultation is free and runs about 45 minutes. Chemotherapy for ovarian cancer is delivered by CION in-house, in day-care units across more than 35 centres in Telangana and Andhra Pradesh, along with maintenance therapy, BRCA and HRD testing, genetic counselling, nutrition support and follow-up. Debulking and other gynaecologic-oncology surgery, along with HIPEC, intraperitoneal chemotherapy and PET-CT, is coordinated with specialist partner centres and may be billed there, and we say so upfront rather than leaving it to be discovered later. Every case that raises a question is reviewed at a tumour board. Costs, insurance and scheme cover such as Aarogyasri are discussed before treatment begins.